GlassScriptPhysician profile
Mihaela Donca
NPI 1881635670
$9,944.77
in general payments reported to CMS, 2019-2025
43 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $237 · 2021: $332 · 2022: $1,765 · 2023: $2,180 · 2024: $3,060 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,475.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,773.94 | 2021-2025 | Ubrelvy, Vraylar, Synthroid |
| Novo Nordisk INC | $945.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $841.29 | 2022-2025 | |
| Lilly USA, LLC | $704.48 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $597.35 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $584.22 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $535.07 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $407.50 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $346.02 | 2019-2025 | |
| Astellas Pharma US INC | $320.80 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $320.01 | 2022-2025 | |
| Exact Sciences Corporation | $280.45 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $257.18 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $244.02 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $196.40 | 2024-2025 | Voquezna |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mihaela Donca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.